Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of CX-4945 in Combination With Gemcitabine and Cisplatin in the Frontline Treatment of Patients With Cholangiocarcinoma

Trial Profile

A Phase I/II Study of CX-4945 in Combination With Gemcitabine and Cisplatin in the Frontline Treatment of Patients With Cholangiocarcinoma

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Silmitasertib (Primary) ; Cisplatin; Gemcitabine
  • Indications Cholangiocarcinoma
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Senhwa Biosciences

Most Recent Events

  • 24 Sep 2022 Results published in the Hepatology
  • 18 Mar 2021 Planned End Date changed from 1 Mar 2021 to 31 May 2021.
  • 17 Jan 2021 Interim Results assessing safety and efficacy of silmitasertib in combination with gemcitabine plus cisplatin in patients with unresectable cholangiocarcinoma, presented at the 2021 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top